ADMA: ADMA Biologics Inc Company Value to Net Income
ADMA Biologics owns raw material collection centers and patents, creating barriers to entry for competitors. Revenues are based on the supply of antibodies to hospitals for the therapy of immunodeficiencies. The success of immunoglobulins has ensured a liquidity surplus and margin growth. The company's P/E time series confirms these fundamentals, while 15.50 forms the current metric value, allowing for an assessment of the business value relative to earnings.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwbxec28.yq-7cu2wow&start=20220704&end=20261111&filename=GURU_Markets_-_ADMA_-_ADMA-Biologics_-_PE-Multiple "ADMA: ADMA Biologics Business Payback Period 07/04/2022 - 11/11/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for ADMA Bio (ADMA)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
- earnings and market multiples details:
ADMA - Net Profit|Net Profit Forecast ADMA Biologics|ADMA - Price to Earnings Ratio|Projected Price to Earnings ADMA Biologics Inc|ADMA - PEG Multiple|EV/EBITDA Multiple ADMA Biologics, Inc.|ADMA - Operating profit before deduction of amortization|Earnings per share for the trailing year ADMA Biologics|ADMA - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months admabiologics.com|ADMA - Earnings growth in current year|Consensus forecast of earnings per share growth for next year ADMA Biologics
Comprehensive company analysis:admabiologics.com ADMA
The P/E ratio relates the market capitalization of ADMA Biologics (ADMA) to its net income, measuring the cost of one dollar of current earnings in the eyes of investors. High expectations for profit growth here clash with operational dependence on plasma collection centers and competitive pressure, making the company's P/E value a key indicator of asset overvaluation should risks arise in immunoglobulin production.
Key competitors
P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple PTGX (Protagonist Therapeutics Inc)|Business Payback Period Immunovant Therapeutics (IMVT)|KNSA - Price to Earnings Ratio|grifols.com (GRFS) - Price to Earnings Ratio|Adaptive Biotechnologies Corporation (ADPT) - Price to Earnings Ratio|Price to Earnings Ratio Celldex Therapeutics Inc|Price to Earnings Ratio AUPH|P/E Multiple BioCryst Corp|Price to Earnings Ratio Vera Therapeutics, Inc. (VERA)|dianthustx.com - Price to Earnings Multiple|P/E Multiple PHVS (Pharvaris)|AbCellera Corp (ABCL) - Market Cap to Earnings|Tourmaline Corp - P/E Multiple|PGEN - P/E Multiple|PHAR: P/E Multiple|Price to Earnings Multiple NKTR|Price to Earnings Ratio Upstream Bio|Price to Earnings Ratio Zenas Bio (ZBIO)|P/E Multiple IMNM|P/E Multiple Gossamer Bio Corp. (GOSS)|KalVista Pharmaceuticals - Price to Earnings Ratio|Company Value to Net Income SEPN|Pieris Pharmaceuticals, Inc. - P/E Multiple|SVRA: Price to Earnings Ratio|RIGL: P/E Multiple|ANAB - Business Payback Period|Price to Earnings Ratio Astria Therapeutics|Market Cap to Earnings engene.com ENGN|Price to Earnings Ratio RAPT Therapeutics (RAPT)|Price to Earnings Ratio JBIO (aerovatetx.com)|Price to Earnings Ratio Aclaris ACRS|Kyverna Therapeutics, Inc (KYTX) - Market Cap to Earnings|Tiziana Life Sciences - P/E Multiple|Market Cap to Net Income Ratio cabalettabio.com (CABA)|VTYX: P/E Multiple|THTX - Business Payback Period|AVTX (Avalo Therapeutics Inc.) - P/E Multiple|Price to Earnings Ratio Eledon Pharmaceuticals, Inc (ELDN)|Price to Earnings Ratio Agenus (AGEN)|Business Payback Period climbbio.com|P/E Multiple ZURA (Zura Bio)|P/E Multiple aTyr Pharma Inc ATYR|Adagene Corp - P/E Multiple|IMA (ImageneBio Inc) - Price to Earnings Multiple|shattucklabs.com (STTK) - Price to Earnings Ratio|Price to Earnings Ratio Equillium|CNTB (Connect Biopharma Holdings) - P/E Multiple|P/E Multiple Immunic Inc|Price to Earnings Ratio Atara Biotherapeutics (ATRA)|IFRX: Market Cap to Net Income|P/E Multiple XFOR (X4 Pharmaceuticals)|Company Value to Net Income ACET|Celularity Corp - P/E Multiple|INMB - P/E Multiple|Barinthus Bio (BRNS) - Price to Earnings Ratio|Kezar Life Sciences Inc - Company Value to Net Income|Price to Earnings Ratio SAB Biotherapeutics|Price to Earnings Ratio akaritx.com (AKTX)|P/E Multiple ENLV|P/E Multiple q32bio.com (QTTB)|GeoVax Labs Inc - Price to Earnings Ratio|Company Value to Net Income EDSA|iBio, Inc. - P/E Multiple|Business Payback Period Carisma Therapeutics CARM|XTL Biopharmaceuticals Ltd. (XTLB) - Price to Earnings Ratio|Price to Earnings Ratio Bolt Biotherapeutics, Inc.|Price to Earnings Ratio HCW Biologics, Inc.|Price to Earnings Ratio Aptevo (APVO)|Price to Earnings Ratio AIM (AIM ImmunoTech Inc.)|P/E Multiple aditxt.com (ADTX)|Price to Earnings Ratio GRI Bio GRI|XRTX: Price to Earnings Multiple|ReShape Lifesciences - P/E Multiple|Market Cap to Earnings Revelation Biosciences Corp|INDP: P/E Multiple|scinai.com (SCNI) - P/E Multiple|CALI (CalciMedica Inc) - P/E Multiple|Price to Earnings Multiple AFMD (Affimed Therapeutics)|Price to Earnings Ratio Allakos Inc. (ALLK)|Price to Earnings Ratio hookipapharma.com HOOK|P/E Multiple IGMS (IGM Biosciences)|P/E Multiple iteostherapeutics.com ITOS|OCEA: Price to Earnings Ratio|Company Value to Net Income TCBP (TC BioPharm (Holdings) Plc)|THRD: P/E Multiple
